Paula Cobb
Direttore/Membro del Consiglio presso PROTHENA CORPORATION PLC
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Paula Cobb
Società | Posizione | Inizio | Fine |
---|---|---|---|
PROTHENA CORPORATION PLC | Direttore/Membro del Consiglio | 01/07/2019 | - |
Independent Dir/Board Member | 01/07/2019 | - | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Paula Cobb
Precedenti posizioni note di Paula Cobb
Società | Posizione | Inizio | Fine |
---|---|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/09/2020 | 01/01/2023 |
DECIBEL THERAPEUTICS, INC. | Direttore operativo | 05/02/2019 | 01/12/2019 |
Corporate Officer/Principal | 01/09/2016 | 05/02/2019 | |
NIGHTSTAR THERAPEUTICS PLC | Direttore/Membro del Consiglio | 13/09/2018 | 07/06/2019 |
Independent Dir/Board Member | 13/09/2018 | 07/06/2019 | |
BIOGEN INC. | Corporate Officer/Principal | 01/11/2010 | 01/01/2016 |
Formazione di Paula Cobb
Amherst College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Regno Unito | 3 |
Irlanda | 2 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 3 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
DECIBEL THERAPEUTICS, INC. | Health Technology |
PROTHENA CORPORATION PLC | Health Technology |
BIOGEN INC. | Health Technology |
Aziende private | 3 |
---|---|
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Paula Cobb
- Esperienza